Sanitized fictional sample. This page illustrates the ClinicOps portfolio transition work-plan format. It is not a compliance determination, legal conclusion, or full-register audit.
ClinicOps Class III Transition Map — Sanitized Sample
As of: 2026-09-10
Work-plan screening from supplied or public metadata. Priority is operator triage only; this report is not a compliance determination, legal conclusion, or full-register EUDAMED audit.
Portfolio snapshot
Prioritised work plan
| Priority | Company | Device | Role | Registration | Certificate expiry | Danish market | Workstream | Evidence source |
|---|---|---|---|---|---|---|---|---|
| 95 | Example MedTech A | Example Class III Device | MF | legacy | 2027-02-15 | confirmed | Legacy → MDR transition: urgent work-plan review | — |
| 30 | Example MedTech B | Example MDR Device | MF | MDR | 2028-06-30 | yes | MDR manufacturer record — monitor document/market-language controls | — |
| 5 | Example Pack Producer | Example Procedure Pack | PR | MDR | — | unknown | Separate PR/system-procedure-pack review | — |
Interpretation constraints
- Separate MF and PR actor-role records before interpreting class or SS(C)P fields.
- Treat B-prefix handling as a derived screening signal, not a quoted Commission rule.
- Do not infer SS(C)P non-compliance solely from a null or absent public link.
- Verify certificate dates and target-market evidence before external reliance.
- Do not describe reachable public-API screening as an end-to-end EUDAMED audit.
Recommended next questions
- Which legacy manufacturer-role devices have the earliest verified certificate or transition dates?
- Which of those devices are confirmed for the relevant target market?
- Who owns Basic UDI-DI, SS(C)P, market-language availability and change-control work for each transition?
- Which evidence is already controlled internally and which must be obtained from the manufacturer, authorised representative or notified body?
Want this applied to a real portfolio?
What to bring: start with a small portfolio export or agreed record set. Known identifiers, certificate timing and target-market context help; missing evidence can stay explicit rather than being guessed.
What a scoped pilot produces: a prioritised work plan, evidence-gap queue and human-reviewed next steps grounded in the supplied or reachable evidence. The responsible regulatory team retains final judgement.
Build an assessment brief · Email ClinicOps directly · Use the free readiness score · Privacy · Back to ClinicOps